November 18, 2026
Health news, explained with evidence
LIVE
Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine

FDA Declines Approval for Novel Lung Cancer Treatment Developed in China

🧠 AI Analysis 1 min read 👁 11

Federal regulators have turned down an application for ivonescimab, an experimental lung cancer therapy invented in China and licensed by a U.S. firm, citing insufficient evidence of prolonged overall survival in clinical trials.

FDA Declines Approval for Novel Lung Cancer Treatment Developed in China🧠AI Analysis

Photo: The New York Times Health

Key points

  • The FDA rejected ivonescimab because it did not significantly prolong patient lives in global trials.
  • The drug successfully delayed cancer progression when combined with chemotherapy.
  • Summit Therapeutics holds the U.S. rights to the medication originally invented by Akeso Biopharma.

Federal Regulators Decline Application for Ivonescimab

The Food and Drug Administration has decided not to approve ivonescimab, a novel intravenous cancer treatment invented by the Chinese drugmaker Akeso Biopharma and licensed for the U.S. market by Florida-based Summit Therapeutics. Regulators pointed out that the global clinical trial, which enrolled patients across North America, Europe, and Asia who had already undergone targeted therapy, failed to demonstrate a statistically significant benefit in extending patients' overall lives.

While the international study showed that combining ivonescimab with chemotherapy successfully delayed cancer progression compared to chemotherapy alone, the company's subsequent unscheduled analyses of longer-term outcomes failed to persuade the agency. Summit representatives argued that slow study enrollment skewed the survival data. The intravenous medication works through a dual mechanism designed to activate the immune system while simultaneously cutting off the tumor's blood supply.

What to know: Ivonescimab remains under investigation in numerous other late-stage clinical trials targeting various tumor types, including colon, bladder, and breast cancers. Patients considering participation in clinical trials or exploring alternative therapies should always consult their oncologist for personalized medical guidance.

Source The New York Times Health — nytimes.com/2026/11/15/business/fda-lung-cancer-drug-china.html ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.